Andrographis — Research Profile

Andrographis has arguably stronger clinical evidence than echinacea, with a Cochrane review of 33 RCTs supporting its use for cold symptoms ^[2]. The effect sizes in andrographis trials tend to be larger and more consistent. Andrographis is better for treatment of active colds, while echinacea may be slightly better for prevention. They can be combined — the Kan Jang formula actually combines andrographis with Eleutherococcus (Siberian ginseng). Andrographis is much more bitter in taste.

Andrographis is one of the most intensely bitter plants used in medicine, and its bitter taste is legendary in Ayurvedic and Chinese traditional practice. The bitterness comes primarily from andrographolide and related diterpenoid lactones. In traditional medicine, bitterness was considered therapeutically important, stimulating digestive secretions and liver function. For modern supplementation, capsules are strongly recommended unless you have a tolerance for extremely bitter flavors.

Short-term use (5-14 days) for acute illness has the best safety data. Long-term safety data is more limited. Animal studies have shown anti-fertility effects at high doses, so andrographis is not recommended during pregnancy or for those trying to conceive. For daily preventive use, lower doses (200-300mg) and periodic cycling (8 weeks on, 2 weeks off) are prudent approaches until more long-term human data is available.

Oral standardized leaf-extract capsules or tablets are the form used in essentially all human trials, and the best-evidenced product is the Kan Jang fixed combination of andrographis with Eleutherococcus for respiratory symptoms. There is no consumer oral form clearly shown to outperform another. Intravenous andrographolide should be avoided outside a medical setting, as it has been linked to acute kidney injury.

The strongest evidence is for short-term relief of uncomplicated upper-respiratory infection symptoms: a systematic review of seven double-blind trials (n=896) found andrographis superior to placebo, and a meta-analysis showed a significant reduction in symptom-severity scores. Evidence for other uses is weaker or negative — a randomized COVID-19 trial found no added clinical or virological benefit, and a systematic review of ulcerative colitis found no significant improvement in clinical response (RR 0.95) or remission (RR 1.31). Most other claimed effects rest on laboratory and animal work rather than human outcomes.

There is no single official dose. Cold and respiratory trials used standardized extracts supplying roughly 4-5.6 mg of andrographolide taken three times daily (typically alongside Eleutherococcus), while a COVID-19 trial used 180 mg/day of andrographis extract and traditional use for fever or sore throat runs 3-6 grams of crude herb daily. Because commercial products vary widely in andrographolide content, dose by the labeled andrographolide amount rather than by capsule count.

Time of day has not been directly compared in trials, so no specific clock time is evidence-based. Respiratory studies dosed it in divided doses across the day during an active infection, which is the pattern to follow. Since the most common complaints are gastrointestinal, taking it with food is a reasonable way to reduce nausea or stomach upset.

In randomized trials non-serious adverse events occurred at about 102.6 per 1,000 patients, most often gastrointestinal (nausea, diarrhea) and skin or subcutaneous reactions. Other reported effects include headache, fatigue, vertigo, rash, lymph-node discomfort, and altered taste. Serious events were very rare (0.02 per 1,000), but allergic reactions including anaphylaxis have been reported with andrographis preparations, so discontinue it if a rash or swelling develops.

Yes. Andrographis inhibits the CYP1A2, CYP2C9, and CYP3A4 enzymes, so it can raise levels of drugs cleared by them (for example aminophylline). It may add to the effect of blood-pressure-lowering drugs, may slow platelet aggregation and so compound anticoagulants or antiplatelet drugs, and because it stimulates immune activity it may oppose immunosuppressant therapy. Its antioxidant activity may also interfere with some chemotherapy drugs, so cancer patients should clear it with their oncologist first.

It is best suited to otherwise-healthy adults wanting short-term relief of early, uncomplicated cold or upper-respiratory symptoms, the use with the strongest trial support. It should be avoided in pregnancy (a possible miscarriage risk), by anyone trying to conceive, and by people with autoimmune disease, bleeding disorders or upcoming surgery, or already-low blood pressure. Anyone on anticoagulants, antihypertensives, immunosuppressants, or CYP-metabolized medications should not start it without medical guidance.

Andrographis is studied as a short-course remedy taken during an active upper-respiratory infection rather than as a slow-building daily tonic. In the seven double-blind trials (n=896) pooled by Coon and Ernst it was superior to placebo for relieving uncomplicated cold and sore-throat symptoms, and a separate meta-analysis found a significant reduction in symptom-severity scores (a 10.85-point difference, P<0.0001) versus placebo. Those reviews do not report a specific time-to-effect, so no reliable onset window is established; practically it is taken while you are ill, and if several days of an active cold bring no improvement, continuing it is unlikely to help.

The safety of continuous long-term use has not been established, because trials have almost all been short courses of days to a few weeks for acute infection. In the safety meta-analysis, serious adverse events were very rare (pooled 0.02 per 1,000 patients) but non-serious events were not uncommon at about 102.6 per 1,000 in RCTs, mostly gastrointestinal and skin reactions. There is no evidence base for taking andrographis daily for months, and animal reproductive and immune-stimulating concerns argue against indefinite use.

There is no established upper limit; oral trials have used up to about 180 mg/day of standardized extract, and traditional crude-herb use runs 3-6 grams daily for fever or sore throat. Pushing past studied amounts mainly raises the risk of the dose-related problems already reported: gastrointestinal upset, rash, and allergic reactions, with enlarged lymph nodes noted at very high doses. Intravenous andrographolide (not an oral supplement use) has caused acute kidney injury, so higher is not safer.

The most-studied andrographis product is itself a fixed combination with Eleutherococcus (Siberian ginseng), so pairing is not inherently a problem. The real caution is metabolic: andrographis inhibits the CYP1A2, CYP2C9, and CYP3A4 enzymes, so it can raise blood levels of other compounds cleared by those pathways. Stacking it with other blood-pressure-lowering or clotting-slowing botanicals (such as garlic or ginkgo) could produce additive effects, so those combinations warrant more care than most.

The active constituents are diterpenoid lactones called andrographolides, so choose an extract that states its andrographolide content per serving rather than just total herb weight. Clinical products are standardized this way, with cold-study formulas supplying roughly 4-5.6 mg of andrographolide per dose. Products modeled on the Kan Jang formulation additionally pair a standardized andrographis extract with Eleutherococcus, which is the specific combination behind most of the respiratory-symptom evidence.